CM101 is a first in class monoclonal antibody directed against a novel target found to be involved in inflammatory and fibrotic processes.
CM-101 has completed seven years of various pre-clinical testing in-vitro, ex-vivo and in-vivo in several animal models. CM101 has been shown to be beneficial in multiple experimental models of NASH, PSC and systemic sclerosis by targeting inflammation and fibrosis independently.
With its lead fully humanized CM101, ChemomAb has completed a phase 1 clinical trial in healthy volunteers which identified a good safety profile as well as pharmacokinetic and target engagement properties.
ChemomAb is currently enrolling patients to a Phase 1b in NAFLD patients. Phase 2 studies in NASH and Primary Sclerosing Cholangitis are underway.